SCHEMBL1897367

SCHEMBL1897367

Cc1cc(C)c2nc(-c3ccc(C)s3)cc(C(=O)Nc3nnc(-c4ccco4)o3)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 4/20 0.57
KDM4E B2RXH2 6/20 0.56
RAB9A P51151 4/20 0.56
NPC1 O15118 3/20 0.56
KMT2A Q03164 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
MEN1 O00255 2/20 0.56
ALDH1A1 P00352 2/20 0.56
MAPT P10636 2/20 0.56
POLB P06746 1/20 0.56
GAA P10253 1/20 0.56
PKM P14618 1/20 0.56
APEX1 P27695 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
RCE1 Q9Y256 1/20 0.56
LMNA P02545 7/20 0.52
ALOX12 P18054 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HTT P42858 2/20 0.51
TP53 P04637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1902843 0.92 STAT3 (0.54) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1897309 0.90 STAT3 (0.72) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1902149 0.82 STAT3 (0.63) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1898262 0.80 STAT3 (0.75) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1898563 0.79 STAT3 (0.67) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1902098 0.78 STAT3 (0.76) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1900227 0.77 STAT3 (0.81) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1899975 0.77 STAT3 (0.66) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1897499 0.76 STAT3 (0.77) STAT3KDM4ERAB9ANPC1KMT2A
SCHEMBL1898646 0.76 STAT3 (0.78) STAT3KDM4EKMT2AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885KDM4E 532/4885RAB9A 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.